#indian-pharma
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturi…
india-rx-mcp 0.1.0
MCP server for Indian pharma regulatory data (CDSCO approvals + NPPA pricing)
Indian industry led by pharma to invest $20.5 billion in the US
Indian pharmaceutical companies plan to invest $20.5 billion in the US, enhancing manufacturing and healthcare supply chains.